文献速递眼底病与葡萄膜炎

利用人工智能评估视网膜色素变性黄斑水肿的治疗

USING ARTIFICIAL INTELLIGENCE TO ASSESS MACULAR EDEMA TREATMENTS IN RETINITIS PIGMENTOSA.
PubMed 文献 · Retina · 2026-01-01

本回顾性纵向研究验证了一种深度学习人工智能工具,用于量化视网膜色素变性黄斑水肿的视网膜内液体积,并通过纵向分析视网膜内液,为治疗疗效和疾病自然史提供新见解。研究发现,口服乙酰唑胺治疗的患眼视网膜内液显著减少,最佳矫正视力显著改善,而局部碳酸酐酶抑制剂治疗无显著变化。

要点

  • 深度学习工具可快速准确量化视网膜色素变性相关黄斑水肿的视网膜内液
  • 口服乙酰唑胺治疗显著减少长期视网膜内液并改善最佳矫正视力
  • 局部碳酸酐酶抑制剂治疗未显示视网膜内液显著变化

核心结论

  • 深度学习工具能快速准确量化视网膜色素变性相关黄斑水肿的视网膜内液
  • 口服乙酰唑胺治疗导致长期视网膜内液显著减少
  • 结构和功能改善仅在口服乙酰唑胺治疗的患眼中显著相关

研究设计与样本

  • 回顾性纵向研究,纳入44例视网膜色素变性合并黄斑水肿患者
  • 治疗分析中,52眼为治疗组,14眼为未治疗黄斑水肿组
  • 使用商用视网膜分析工具量化视网膜内液,并通过谱域光学相干断层扫描体积扫描验证分割

主要发现

  • 软件验证比较自动与手动视网膜内液分割的490对图像,Dice系数为0.928(95%CI:0.92‒0.99)
  • 基线时队列平均视网膜内液体积为230.85 nL(57.42,403.91)
  • 局部碳酸酐酶抑制剂治疗眼视网膜内液变化为-2.1 nL/年(P=0.81)
  • 口服乙酰唑胺治疗眼视网膜内液显著减少(-33.6 nL/年,P=0.009)
  • 口服乙酰唑胺治疗眼最佳矫正视力显著改善(logMAR/年;ETDRS字母等效)(-0.041;+2字母)(P=0.025)

临床怎么用

  • 原文未据此给出推荐

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This study validates a deep learning-based artificial intelligence tool for quantifying macular edema (ME) intraretinal fluid (IRF) volumes in retinitis pigmentosa, and through longitudinal analysis of IRF, provides new insight into treatment efficacy and disease natural history. METHODS: This retrospective, longitudinal study identified patients with retinitis pigmentosa with ME. A commercially available retinal analysis tool quantified IRF and was validated for segmentation of ME using spectral-domain optical coherence tomography volume scans. Baseline analysis of IRF versus traditional central subfield thickness and longitudinal analyses of IRF versus treatment and best-corrected visual acuity were performed. RESULTS: Forty-four patients were identified. For treatment studies, 52 eyes were in the treated group and 14 eyes in the untreated ME group. Mean follow-up was 5.3 exams (3.7, 6.9) over 2.3 years (1.7, 3.0). Software validation compared automated and manual IRF segmentation of 490 image pairs, finding a Dice coefficient of 0.928 (95% confidence interval: 0.92‒0.99). Cohort mean IRF volume was 230.85 nL (57.42, 403.91) at baseline. Intraretinal fluid change in eyes treated with topical carbonic anhydrase inhibitors was -2.1 nL/year ( P = 0.81). Oral acetazolamide-treated eyes had significant IRF reduction (-33.6 nL/year, P = 0.009) and significant improvements in best-corrected visual acuity (logMAR/year; Early Treatment Diabetic Retinopathy Study letters equivalent) (-0.041; +2 letters) ( P = 0.025). CONCLUSION: A deep learning tool was able to rapidly and accurately quantify IRF in retinitis pigmentosa-associated ME. Using this analysis tool, we confirmed that treatment with acetazolamide led to significant reduction in long-term IRF. Structural changes (IRF) only translated to significant functional improvements (best-corrected visual acuity) in eyes treated with acetazolamide.

来源:Retina,查看原文。版权归原作者所有。

引用

  1. Most JA, Walker EH, Le AD, et al. USING ARTIFICIAL INTELLIGENCE TO ASSESS MACULAR EDEMA TREATMENTS IN RETINITIS PIGMENTOSA. Retina. 2026. PMID: 40743462. doi:10.1097/IAE.0000000000004636

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。